NucleoBio and PreCheck Health Services Announce Strategic Collaboration to Advance Non-Invasive Prostate Cancer Testing
NucleoBio, Corp., a leading biotechnology innovator in precision oncology diagnostics, and PreCheck Health Services, a high-complexity CLIA-certified and CAP-accredited clinical laboratory, today announced a strategic collaboration to support clinical development and processing of the proprietary Prostac™ assay. This partnership aims to enable future application of the test across a broader clinical setting, supporting ongoing research and validation efforts for early detection and risk stratification in prostate cancer.
